Aclarion Announces Key Commercial Milestone With Completion of 1,000 Nociscan Exams, All Commercial Nociscans To Date Have Been Completed On Siemens MRI Scanners With Additional Acceleration Of Volumes Expected As Philips Scanners Are Onboarded
Portfolio Pulse from Benzinga Newsdesk
Aclarion, Inc. has reached a significant commercial milestone by completing 1,000 Nociscan exams, all of which have been conducted on Siemens MRI scanners. The company anticipates further acceleration of exam volumes as Philips MRI scanners are integrated into their service offerings.
November 27, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aclarion, Inc. has completed 1,000 Nociscan exams, exclusively using Siemens MRI scanners, and expects increased volumes with the addition of Philips scanners.
The completion of 1,000 Nociscan exams is a significant achievement for Aclarion, indicating successful adoption and utilization of their technology. The exclusive use of Siemens MRI scanners so far shows a strong partnership, and the anticipated integration of Philips scanners suggests potential for increased market penetration and revenue growth. This news is likely to be viewed positively by investors, potentially leading to a short-term increase in Aclarion's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
POSITIVE IMPACT
Philips is expected to have an increased role in Aclarion's service offerings as their MRI scanners are being onboarded, which may lead to growth in Philips' medical imaging business.
The onboarding of Philips MRI scanners for use in Aclarion's Nociscan exams represents a new business opportunity for Philips. This expansion into Aclarion's offerings could lead to increased usage and sales of Philips MRI scanners, potentially benefiting Philips' medical imaging segment. The news may have a positive short-term impact on Philips' stock as it suggests growth prospects in a specific product line.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 60
POSITIVE IMPACT
Siemens has been the exclusive provider of MRI scanners for Aclarion's 1,000 Nociscan exams, which may reflect positively on Siemens' market presence in MRI technology.
Siemens' exclusive role in Aclarion's milestone of 1,000 Nociscan exams highlights the company's strong presence in the MRI scanner market. While the news is primarily about Aclarion, it indirectly benefits Siemens by demonstrating the reliability and preference for Siemens MRI technology in the healthcare industry. This could have a positive short-term impact on Siemens' stock as it reinforces the company's market position.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 60